Cost-effectiveness of reduction mammaplasty.

https://arctichealth.org/en/permalink/ahliterature70902
Source
Int J Technol Assess Health Care. 2004;20(3):269-73
Publication Type
Article
Date
2004
Author
Andrew J Taylor
David Tate
Yvonne Brandberg
Lennart Blomqvist
Author Affiliation
University of Hull, Hull, UK.
Source
Int J Technol Assess Health Care. 2004;20(3):269-73
Date
2004
Language
English
Publication Type
Article
Keywords
Adult
Aged
Breast - pathology - surgery
Cost-Benefit Analysis
Female
Humans
Hypertrophy
Mammaplasty - economics
Middle Aged
Quality-Adjusted Life Years
Abstract
OBJECTIVES: The purpose of this study is to provide a comparison of the benefits of reduction mammaplasty (RM) for women with heavy breasts often termed macromastia or breast hypertrophy (BH) surgery. The rationale is to provide information to allow decision-makers to make judgments about the cost-effectiveness of this intervention and make comparisons with other interventions which are commonly undertaken within publicly financed health-care systems. METHODS: Data from a previous outcomes study in Sweden is re-analyzed to derive quality of life measures, from which a mean level of benefit outcome is derived and a cost per quality-adjusted life year is calculated (cost per QALY). RESULTS: The low Cost per QALY suggests that reduction mammaplasty is cost-effective when compared with other treatments which are commonly undertaken. CONCLUSIONS: The authors suggest that the evidence in favor of funding reduction mammaplasty is strong and that decision-makers review their policy in light of this new evidence.
PubMed ID
15446755 View in PubMed
Less detail